CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BTP53ALTERATIONPrognosticSupportsPoor OutcomeOvarian CancerReles et al., 2001
ABRAFV600EPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrametinib,DabrafenibPlanchard et al., 2016
BAKT1E17KPredictiveSupportsSensitivity/ResponseCancerCapivasertibHyman et al., 2017
BPIK3CAMutationPredictiveSupportsSensitivity/ResponseCancerCapivasertibHyman et al., 2017
DTP53R248QPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
BKRASMutationPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
BBRAFV600EPredictiveSupportsResistanceColorectal CancerFOLFOX-4 Regimen,CetuximabKaczirek et al., 2015
BBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibTrunzer et al., 2013
BBRAFV600EPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinib,DabrafenibRobert et al., 2015
BEGFRL858R OR EGFR Exon 19 DeletionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaErlotinibRosell et al., 2012
BKRASQ61PredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
DKRASG12RPredictiveSupportsResistanceColorectal CancerCetuximabMisale et al., 2012
CEGFRE746_A750delPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibPao et al., 2004
CEGFRMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibBrugger et al., 2011
CBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
BBCR::ABL1Fusion AND ABL1 M351TPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 F359CPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
DBRAFV600DPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibYang et al., 2010
CEGFRD770_N771insGLPredictiveSupportsResistanceLung AdenocarcinomaErlotinibYasuda et al., 2013
DKITT670IPredictiveSupportsResistanceGastrointestinal Stromal TumorRegorafenib AnhydrousGarner et al., 2014
DKITD816EPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinib,SunitinibGarner et al., 2014
CBCR::ABL1FusionPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
BEGFRRare Exon 18-21 MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib,ErlotinibWu et al., 2011
BEGFRL858R OR EGFR Exon 19 DeletionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibWu et al., 2011
DABL1R351WPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinibTestoni et al., 2016
CEGFRD770delinsGYPredictiveSupportsResistanceLung AdenocarcinomaErlotinibYasuda et al., 2013
BVHLMutationPredictiveDoes Not SupportSensitivity/ResponseRenal Cell CarcinomaAnti-VEGF Monoclonal AntibodyKim et al., 2017
DIDH2MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaEnasidenibYen et al., 2017
Bv::ALKFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaBrigatinibKim et al., 2017
BBRCA1Loss-of-functionPredictiveSupportsSensitivity/ResponseBreast CancerTalazoparibde Bono et al., 2017
BBRCA2Loss-of-functionPredictiveSupportsSensitivity/ResponseBreast CancerTalazoparibde Bono et al., 2017
BERBB2OverexpressionPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerTrastuzumab EmtansineDiéras et al., 2017
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaTrametinibBlumenschein et al., 2015
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,SelumetinibCarter et al., 2016
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerPalbociclib,BinimetinibLee et al., 2016
DFGFR3S249CPredictiveSupportsSensitivity/ResponseCancerInfigratinib,PD173074Chandrani et al., 2017
DCDK4EXPRESSIONPredictiveSupportsSensitivity/ResponseSarcomaPalbociclibPerez et al., 2015
DCHEK1OverexpressionPredictiveSupportsSensitivity/ResponseLung Small Cell CarcinomaOlaparib,Cisplatin,PrexasertibSen et al., 2017
DTP53R248WPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R273CPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R273HPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53G245SPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53Y220CPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53V157FPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R249SPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R280KPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R280TPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R158LPredictiveSupportsResistanceLung AdenocarcinomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
CVHLE46* (c.136G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
Page 15 of 96
PreviousNext